Regulatory bodies in Hong Kong and Argentina have approved Vyzulta for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.
Bausch & Lomb, Nicox’s partner, received the approvals for commercialization of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%).
Nicox will receive tiered net royalties of 6% to 12% on global Vyzulta sales, as well as milestone payments up to $150 million.
Uncategorized